TABLE 2.
Most common regorafenib‐related treatment toxicities (CTCAE version 4.03), n = 30 evaluable patients
| Adverse event | CTCAE Severity (number of patients) | |||
|---|---|---|---|---|
| Grade 1–2 | Grade 3 | Grade 4 | Total | |
| Hypophosphatemia | 0 | 5 | 1 | 6 |
| Hypertension | 3 | 2 | 0 | 5 |
| Alanine aminotransferase increased | 0 | 2 | 0 | 2 |
| Mucositis, oral | 7 | 1 | 0 | 8 |
| Diarrhea | 3 | 1 | 0 | 4 |
| Fatigue | 1 | 1 | 0 | 2 |
| Abdominal pain | 1 | 1 | 0 | 2 |
| Rash, maculo‐papular | 1 | 1 | 0 | 2 |
| Aspartate aminotransferase increased | 1 | 1 | 0 | 2 |
| Hypokalemia | 0 | 1 | 0 | 1 |
| Neutrophil count decreased | 0 | 1 | 0 | 1 |
| Lipase increased | 0 | 1 | 0 | 1 |
| Palmar‐plantar erythrodysesthesia syndrome | 13 | 0 | 0 | 13 |
| Nausea/vomiting | 7 | 0 | 0 | 7 |
| Voice alteration | 3 | 0 | 0 | 3 |
| Headache | 3 | 0 | 0 | 3 |
| Blood bilirubin increased | 2 | 0 | 0 | 2 |
| Fever | 1 | 0 | 0 | 1 |
| Alopecia | 1 | 0 | 0 | 1 |
| White blood cell decreased | 1 | 0 | 0 | 1 |
| Platelet count decreased | 1 | 0 | 0 | 1 |
| Anorexia | 1 | 0 | 0 | 1 |
| Back pain | 1 | 0 | 0 | 1 |
| Constipation | 1 | 0 | 0 | 1 |
| Erythema multiforme | 1 | 0 | 0 | 1 |
| Malaise | 1 | 0 | 0 | 1 |
| Myalgia | 1 | 0 | 0 | 1 |
| Peripheral nerve infection | 1 | 0 | 0 | 1 |
| Upper respiratory infection | 1 | 0 | 0 | 1 |
| Total | 57 | 18 | 1 | 76 |